This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.
Editorial Podcasts
Advertisement
Learn Morewww.bio-rad.com/fluvaccine
Advertisement
Dennis Brandl, President, at BR&L Consulting, spoke with BioPharm International about what should be expected when transitioning from paper to EBR.
Don Frail, Vice President, AstraZeneca Innovative Medicines Group discusses the company's approach to innovation and the upcoming session at the BIO International Convention
Advertisement
A conversation with Armand Keating, the Epstein Chair in Cell Therapy and Transplantation at the University of Toronto prior to his presentation at Bio 2013
In recent years, large pharmaceutical companies have launched a variety of initiatives to restock ailing pipelines and boost business performance including mergers and acquisitions, diversifying business portfolios to non-pharmaceutical products, downsizing, spinoffs, and entering the biopharmaceutical arena.
BioPharm International interviews Tarja Mottram, CEO of Action for Results, on the marriage of science and business to ensure sustainable growth. Posted Feb. 2012.
Mike Ultee, chief scientific officer of Laureate Biopharmaceutical Services, discusses advances in separations technology, beginning with the 1988 publication of ?Separations Technology Outlook, Part II? by Nancy E. Pfund and Kathleen G. Charles.
Advertisement
Advertisement
Trending on BioPharm International
1
Q&A: An Evolution in Enzyme Engineering with Zymvol’s Marina Cañellas
2
Regulatory Challenges for Global Manufacturing of Vaccines
3
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
4
Welcome to CPHI Frankfurt 2025
5
